Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Ronglei Li"'
Publikováno v:
ACS Omega, Vol 9, Iss 39, Pp 40531-40549 (2024)
Externí odkaz:
https://doaj.org/article/0ee5c7108d1c4fdaae514b065efaf280
Autor:
Fang Lv, Ruidong Yang, Tongsheng Yi, Wei Gao, Xu Wang, Wei Cheng, Yan Zhang, Ronglei Li, Zhihua Yan, Yaohui Liu, Geng Li
Publikováno v:
Frontiers in Earth Science, Vol 10 (2023)
In-situ stress is an important indicator for the preferential selection of coalbed methane (CBM) exploration dessert zones, and is a key factor affecting the production capacity of coalbed methane wells. Coal reservoir permeability is one of the key
Externí odkaz:
https://doaj.org/article/78de723a23954e8bb7dca33632fb1f6e
Autor:
Xiaorong Zhou, Chenchen Li, Zhao Zhang, Daniel Y. Li, Jinwei Du, Ping Ding, Haiyan Meng, Hui Xu, Ronglei Li, Effie Ho, Aiguo Zhang, Paul Okunieff, Jianwei Lu, Michael Y. Sha
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
Abstract Tyrosine kinase inhibitors (TKIs), VEGF/VEGF receptor inhibitors (VEGFIs) and immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced cancers including non-small-cell lung cancer (NSCLC). This study aims to evaluate
Externí odkaz:
https://doaj.org/article/b2343cf2b10446a4ab9c404bea005c66
Publikováno v:
Natural Resources Research. 32:295-319
Autor:
Effie Ho, Paul Okunieff, Hui Xu, Michael Y. Sha, Jianwei Lu, Chenchen Li, Xiaorong Zhou, Ping Ding, Daniel Y. Li, Aiguo Zhang, Zhao Zhang, Haiyan Meng, Ronglei Li, Jinwei Du
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
Scientific Reports
Scientific Reports
Background: Tyrosine Kinases Inhibitors (TKIs), VEGF/VEGF receptor inhibitors (VEGFIs, bevacizumab) and immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced cancer including non-small-cell lung cancer (NSCLC). Cell-free D
Autor:
Xiaorong Zhou, Aiguo Zhang, Jinwei Du, Paul Okunieff, Zhao Zhang, Ronglei Li, Chenchen Li, Jianwei Lu, Daniel Y. Li, Effie Ho, Michael Y. Sha
BackgroundTyrosine Kinases Inhibitors (TKIs), VEGF/VEGF receptor inhibitors (VEGFIs, bevacizumab) and immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced cancer including non-small-cell lung cancer (NSCLC). Cell-free DNA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a57110f3a4068a6bd46e6073bd89dbcc
https://doi.org/10.1101/2020.08.05.238626
https://doi.org/10.1101/2020.08.05.238626